As Majority Of U.S. Patients Tested For JCV, Tysabri Sales Rise, Elan Says

The Irish company is still dealing with the after-effects of splitting apart its business in 2011, including its search for a new CEO. Meanwhile, Elan’s lead revenue driver, Tysabri continues to grow.